Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 6:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Primary Sclerosing Cholangitis (PSC) Clear all
Active, not recruiting No phase listed Observational

Liver Cirrhosis Network Cohort Study

NCT05740358
View directory record Official record
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jun 10, 2026, 6:49 AM EDT
Not listed No phase listed Observational

Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study

NCT03951324
View directory record Official record
Conditions
Biliary Stricture, Pancreas Cancer, Cholangiocarcinoma, Bile Duct Cancer, Bile Duct Neoplasms Malignant, Bile Duct Neoplasms, Bile Duct Lesions, Bile Duct Obstruction, Bile Duct Diseases, Bile Duct Obstruction, Extrahepatic, Bile Duct Stenosi, Bile Duct Adenoma, Pancreatic Duct Stricture, Pancreatic Duct Stenosis, Pancreatic Duct Obstruction, Pancreatic Ductal Adenocarcinoma, Primary Sclerosing Cholangitis
Interventions
Interobserver agreement or Interrater agreement
Other
Lead sponsor
Innovative Digestive Health Education and Research Inc
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Jun 10, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

NCT04480840
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
PLN-74809, Placebo
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
21
States / cities
Pasadena, California • Redwood City, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jun 10, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

NCT02943460
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Cilofexor, Placebo to match cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
16
States / cities
Sacramento, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Jun 10, 2026, 6:49 AM EDT
Terminated Phase 1 Interventional Results available

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

NCT04060147
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Compensated Cirrhosis
Interventions
Cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
16
States / cities
Chandler, Arizona • Pasadena, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jun 10, 2026, 6:49 AM EDT
Withdrawn Not applicable Interventional

Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients

NCT03046901
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Post- Orthotopic Liver Transplantation
Interventions
Vancomycin
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Jun 10, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Results available

Vidofludimus Calcium for Primary Sclerosing Cholangitis

NCT03722576
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Vidofludimus calcium
Drug
Lead sponsor
Elizabeth Carey
Other
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Phoenix, Arizona • Tempe, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Jun 10, 2026, 6:49 AM EDT
Recruiting No phase listed Observational

A-LiNK: Improving Outcomes in Autoimmune Liver Disease

NCT05750498
View directory record Official record
Conditions
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Interventions
No interventions
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
8
States / cities
Palo Alto, California • Indianapolis, Indiana • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Jun 10, 2026, 6:49 AM EDT
Recruiting No phase listed Observational

MRI Based Biomarkers in Pediatric Autoimmune Liver Disease

NCT03175471
View directory record Official record
Conditions
Autoimmune Liver Disease, Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 23 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Jun 10, 2026, 6:49 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis

NCT01088607
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
ursodeoxycholic acid (UDCA)
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
5 Years to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Jun 10, 2026, 6:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC)

NCT02978339
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Curcumin
Drug
Lead sponsor
John E. Eaton
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jun 10, 2026, 6:49 AM EDT
Enrolling by invitation No phase listed Observational

TruGraf Liver Gene Expression Serial Test

NCT06061341
View directory record Official record
Conditions
Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
Interventions
TruGraf®
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jun 10, 2026, 6:49 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

NCT06699121
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
LB-P8 low-dose, LB-P8 high-dose, Placebo
Drug
Lead sponsor
LISCure Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Sacramento, California • Aurora, Colorado • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jun 10, 2026, 6:49 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

NCT02137668
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Biliary Atresia
Interventions
Oral Vancomycin
Drug
Lead sponsor
Sacramento Pediatric Gastroenterology
Other
Eligibility
2 Weeks to 40 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2028
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2016 · Synced Jun 10, 2026, 6:49 AM EDT
Recruiting Early Phase 1 Interventional

Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC

NCT06197308
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
oral vancomycin and oral amoxicillin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 76 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 10, 2026, 6:49 AM EDT
Recruiting No phase listed Observational

Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)

NCT06297993
View directory record Official record
Conditions
PSC
Interventions
Not listed
Lead sponsor
PSC Partners Seeking a Cure
Other
Eligibility
18 Years to 75 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
11
States / cities
Sacramento, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jun 10, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Results available

A POC and Dose-Ranging Study of HTD1801 in PSC Patients

NCT03333928
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
HTD1801, Placebo
Drug
Lead sponsor
HighTide Biopharma Pty Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Chandler, Arizona • Tuscon, Arizona • Fresno, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Jun 10, 2026, 6:49 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

NCT03183570
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, Covid19 Pneumonia
Interventions
[18F]FP-R01-MG-F2
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jun 10, 2026, 6:49 AM EDT
Completed Phase 1 Interventional

Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis

NCT01456468
View directory record Official record
Conditions
Cholangitis, Sclerosing
Interventions
Oral all-trans retinoic acid (ATRA)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
New Haven, Connecticut • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Jun 10, 2026, 6:49 AM EDT
Terminated Phase 2 Interventional Results available

Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)

NCT00953615
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Thalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 72 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Jun 10, 2026, 6:49 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

NCT05627362
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Elafibranor 80 mg, Elafibranor 120 mg, Placebo Matched to Elafibranor 80 mg, Placebo Matched to Elafibranor 120 mg
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
30
States / cities
Lancaster, California • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 10, 2026, 6:49 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pilot Study of Fenofibrate for PSC

NCT01142323
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
fenofibrate
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Gainesville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Jun 10, 2026, 6:49 AM EDT
Recruiting Phase 1 Interventional

A Study of SIPLIZUMAB in AILD and LT Patients

NCT06455280
View directory record Official record
Conditions
Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, End Stage Liver DIsease, Cirrhosis, Liver
Interventions
Siplizumab
Drug
Lead sponsor
Elizabeth C. Verna
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jun 10, 2026, 6:49 AM EDT
Completed Not applicable Interventional

Quality of Life in Patients With Primary Sclerosing Cholangitis

NCT02712736
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
quality of life survey
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Jun 10, 2026, 6:49 AM EDT